Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1990 2
1991 2
1994 1
1998 2
2005 1
2007 4
2008 3
2009 6
2010 6
2011 5
2012 3
2013 5
2014 3
2015 2
2016 1
2017 3
2018 3
2019 5
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. De Roock W, et al. Among authors: claes b. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Maughan TS, et al. Among authors: claes b. Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5. Lancet. 2011. PMID: 21641636 Free PMC article. Clinical Trial.
Imaging Isomers on a Biological Surface: A Review.
Claes BSR, Takeo E, Fukusaki E, Shimma S, Heeren RMA. Claes BSR, et al. Mass Spectrom (Tokyo). 2019;8(1):A0078. doi: 10.5702/massspectrometry.A0078. Epub 2019 Dec 27. Mass Spectrom (Tokyo). 2019. PMID: 32158629 Free PMC article.
Integrating Metabolomics, Genomics, and Disease Pathways in Age-Related Macular Degeneration: The EYE-RISK Consortium.
Acar İE, Lores-Motta L, Colijn JM, Meester-Smoor MA, Verzijden T, Cougnard-Gregoire A, Ajana S, Merle BMJ, de Breuk A, Heesterbeek TJ, van den Akker E, Daha MR, Claes B, Pauleikhoff D, Hense HW, van Duijn CM, Fauser S, Hoyng CB, Delcourt C, Klaver CCW, Galesloot TE, den Hollander AI; EYE-RISK Consortium. Acar İE, et al. Among authors: claes b. Ophthalmology. 2020 Dec;127(12):1693-1709. doi: 10.1016/j.ophtha.2020.06.020. Epub 2020 Jun 14. Ophthalmology. 2020. PMID: 32553749 Free article.
Simultaneous Detection of Zinc and Its Pathway Metabolites Using MALDI MS Imaging of Prostate Tissue.
Andersen MK, Krossa S, Høiem TS, Buchholz R, Claes BSR, Balluff B, Ellis SR, Richardsen E, Bertilsson H, Heeren RMA, Bathen TF, Karst U, Giskeødegård GF, Tessem MB. Andersen MK, et al. Among authors: claes bsr. Anal Chem. 2020 Feb 18;92(4):3171-3179. doi: 10.1021/acs.analchem.9b04903. Epub 2020 Jan 28. Anal Chem. 2020. PMID: 31944670 Free PMC article.
Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.
Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, Bogaert E, Claes B, Heylen L, Verheyen A, Raes K, Tjwa M, Eriksson U, Shibuya M, Nuydens R, Van Den Bosch L, Meert T, D'Hooge R, Sendtner M, Robberecht W, Carmeliet P. Poesen K, et al. Among authors: claes b. J Neurosci. 2008 Oct 15;28(42):10451-9. doi: 10.1523/JNEUROSCI.1092-08.2008. J Neurosci. 2008. PMID: 18923022 Free PMC article.
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page